470 related articles for article (PubMed ID: 17615271)
1. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors.
Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Hebbel RP; Galipeau J; Hough C; Lillicrap D
Stem Cells; 2007 Oct; 25(10):2660-9. PubMed ID: 17615271
[TBL] [Abstract][Full Text] [Related]
2. Omental implantation of BOECs in hemophilia dogs results in circulating FVIII antigen and a complex immune response.
Ozelo MC; Vidal B; Brown C; Notley C; Hegadorn C; Webster S; Harpell L; Ahlin J; Winterborn A; Handforth J; Arruda VR; Hough C; Lillicrap D
Blood; 2014 Jun; 123(26):4045-53. PubMed ID: 24829206
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
Chuah MK; Schiedner G; Thorrez L; Brown B; Johnston M; Gillijns V; Hertel S; Van Rooijen N; Lillicrap D; Collen D; VandenDriessche T; Kochanek S
Blood; 2003 Mar; 101(5):1734-43. PubMed ID: 12406898
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A.
Doering CB; Denning G; Shields JE; Fine EJ; Parker ET; Srivastava A; Lollar P; Spencer HT
Hum Gene Ther; 2018 Oct; 29(10):1183-1201. PubMed ID: 30160169
[TBL] [Abstract][Full Text] [Related]
5. Use of blood outgrowth endothelial cells for gene therapy for hemophilia A.
Lin Y; Chang L; Solovey A; Healey JF; Lollar P; Hebbel RP
Blood; 2002 Jan; 99(2):457-62. PubMed ID: 11781225
[TBL] [Abstract][Full Text] [Related]
6. Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction.
Tiede A; Eder M; von Depka M; Battmer K; Luther S; Kiem HP; Ganser A; Scherr M
Gene Ther; 2003 Oct; 10(22):1917-25. PubMed ID: 14502221
[TBL] [Abstract][Full Text] [Related]
7. Efficient production of human FVIII in hemophilic mice using lentiviral vectors.
Kootstra NA; Matsumura R; Verma IM
Mol Ther; 2003 May; 7(5 Pt 1):623-31. PubMed ID: 12718905
[TBL] [Abstract][Full Text] [Related]
8. A novel cell-sheet technology that achieves durable factor VIII delivery in a mouse model of hemophilia A.
Tatsumi K; Sugimoto M; Lillicrap D; Shima M; Ohashi K; Okano T; Matsui H
PLoS One; 2013; 8(12):e83280. PubMed ID: 24358271
[TBL] [Abstract][Full Text] [Related]
9. Generation of an optimized lentiviral vector encoding a high-expression factor VIII transgene for gene therapy of hemophilia A.
Johnston JM; Denning G; Doering CB; Spencer HT
Gene Ther; 2013 Jun; 20(6):607-15. PubMed ID: 22996197
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
[TBL] [Abstract][Full Text] [Related]
11. Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity.
Kuether EL; Schroeder JA; Fahs SA; Cooley BC; Chen Y; Montgomery RR; Wilcox DA; Shi Q
J Thromb Haemost; 2012 Aug; 10(8):1570-80. PubMed ID: 22632092
[TBL] [Abstract][Full Text] [Related]
12. Sustained expansion and transgene expression of coagulation factor VIII-transduced cord blood-derived endothelial progenitor cells.
Herder C; Tonn T; Oostendorp R; Becker S; Keller U; Peschel C; Grez M; Seifried E
Arterioscler Thromb Vasc Biol; 2003 Dec; 23(12):2266-72. PubMed ID: 14551158
[TBL] [Abstract][Full Text] [Related]
13. Directed engineering of a high-expression chimeric transgene as a strategy for gene therapy of hemophilia A.
Doering CB; Denning G; Dooriss K; Gangadharan B; Johnston JM; Kerstann KW; McCarty DA; Spencer HT
Mol Ther; 2009 Jul; 17(7):1145-54. PubMed ID: 19259064
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic levels of human factor VIII in mice implanted with encapsulated cells: potential for gene therapy of haemophilia A.
García-Martín C; Chuah MK; Van Damme A; Robinson KE; Vanzieleghem B; Saint-Remy JM; Gallardo D; Ofosu FA; Vandendriessche T; Hortelano G
J Gene Med; 2002; 4(2):215-23. PubMed ID: 11933222
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow mesenchymal cells for haemophilia A gene therapy using retroviral vectors with modified long-terminal repeats.
Van Damme A; Chuah MK; Dell'accio F; De Bari C; Luyten F; Collen D; VandenDriessche T
Haemophilia; 2003 Jan; 9(1):94-103. PubMed ID: 12558785
[TBL] [Abstract][Full Text] [Related]
16. Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer.
Kang Y; Xie L; Tran DT; Stein CS; Hickey M; Davidson BL; McCray PB
Blood; 2005 Sep; 106(5):1552-8. PubMed ID: 15886327
[TBL] [Abstract][Full Text] [Related]
17. Codon optimization of human factor VIII cDNAs leads to high-level expression.
Ward NJ; Buckley SM; Waddington SN; Vandendriessche T; Chuah MK; Nathwani AC; McIntosh J; Tuddenham EG; Kinnon C; Thrasher AJ; McVey JH
Blood; 2011 Jan; 117(3):798-807. PubMed ID: 21041718
[TBL] [Abstract][Full Text] [Related]
18. Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated.
Chen Y; Luo X; Schroeder JA; Chen J; Baumgartner CK; Hu J; Shi Q
J Thromb Haemost; 2017 Oct; 15(10):1994-2004. PubMed ID: 28799202
[TBL] [Abstract][Full Text] [Related]
19. Sustaining expression of B domain-deleted human factor VIII mediated by using lentiviral vectors in NOD/SCID mouse.
Li YJ; Chen C; Zeng LY; Cao J; Xu KL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):658-63. PubMed ID: 22739177
[TBL] [Abstract][Full Text] [Related]
20. Hemophilia Gene Therapy: Ready for Prime Time?
VandenDriessche T; Chuah MK
Hum Gene Ther; 2017 Nov; 28(11):1013-1023. PubMed ID: 28793786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
